Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.70 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.70 |
| ▸ | PTGIR | P43119 | 2/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.70 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | CKS1B | P61024 | 6/20 | 0.61 |
| ▸ | SKP1 | P63208 | 6/20 | 0.61 |
| ▸ | SKP2 | Q13309 | 6/20 | 0.61 |
| ▸ | CNR1 | P21554 | 4/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132049 | 1.00 | NR1I2 (0.70) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| Acetic Acid SCHEMBL29068588 | 0.95 | NR1I2 (0.71) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL19823442 | 0.91 | NR1I2 (0.64) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL28690593 | 0.89 | NR1I2 (0.70) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL21496595 | 0.88 | NR1I2 (0.68) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL19820820 | 0.88 | NR1I2 (0.68) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL19672299 | 0.88 | NR1I2 (0.57) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL5211665 | 0.87 | NR1I2 (0.67) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL3697913 | 0.87 | NR1I2 (0.70) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL14477527 | 0.87 | NR1I2 (0.55) | NR1I2ADORA3TBXA2RAGTR1PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115825304-B | Method for measuring related substances in selapage bulk drug by high performance liquid chromatography | 湖南方盛制药股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119320360-A | In the selapage Process for the preparation of intermediates | 重庆圣华曦药业股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| CN-116947766-A | Preparation method of celecoxib intermediate | 普济生物科技（台州）有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-109384734-B | Preparation method of Selsemipa intermediate | 上海科胜药物研发有限公司 | 2023-04-11 | — | — | CN | claimed |
| US-20260035352-A1 | Inhibitors of Platelet Function and Methods for Use of the Same | UNIV MICHIGAN REGENTS (US) | 2026-02-05 | — | — | US | disclosed |
| CN-119528826-A | Selapage impurity and preparation method thereof | 北京诺康达医药科技股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-115825304-B | Method for measuring related substances in selapage bulk drug by high performance liquid chromatography | 湖南方盛制药股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119320360-A | In the selapage Process for the preparation of intermediates | 重庆圣华曦药业股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-119320360-A | In the selapage Process for the preparation of intermediates | 重庆圣华曦药业股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-119143682-A | Selapa (Seapa) lattice intermediates preparation method of selapage | 湖北生物医药产业技术研究院有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2024195446-A1 | METHOD FOR PRODUCING 4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]-1-BUTANOL CRYSTAL | 株式会社トクヤマ | 2024-09-26 | — | — | WO | disclosed |
| WO-2024195447-A1 | METHOD FOR PRODUCING 4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]-1-BUTANOL | 株式会社トクヤマ | 2024-09-26 | — | — | WO | disclosed |
| CN-118146165-A | 2,3, 5-Trisubstituted pyrazine compound and preparation method and application thereof | 郑州大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-114213343-B | Preparation and purification methods of celecoxib intermediate | 江苏豪森药业集团有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-113968824-B | 2,3, 5-trisubstituted pyrazine compound and preparation method and application thereof | 郑州大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-116947766-A | Preparation method of celecoxib intermediate | 普济生物科技（台州）有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-109384734-B | Preparation method of Selsemipa intermediate | 上海科胜药物研发有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115825304-A | Method for measuring related substances in selepatag bulk drug by high performance liquid chromatography | 湖南方盛制药股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-114213343-A | Preparation and purification method of celecoxib intermediate | 江苏豪森药业集团有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114213343-A | Preparation and purification method of celecoxib intermediate | 江苏豪森药业集团有限公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035352-A1 | Inhibitors of Platelet Function and Methods for Use of the Same | TFPI, MPL, PF4 | NR1I2 4716/4885ADORA3 1804/4885TBXA2R 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.